BioNTech, moderna, curevac, covid-19, koronavirus, vakcina:
20200320AD
BTM Inovacije, javno-privatno partnerstvo, Apeiron, SRI International, Iktos, antivirusni lekovi, AdaptVac, ExpreS2ion biotehnologije, pfizer, janssen, sanofi,

Europska komisija je 16. marta objavila da je ponudila 80 milijuna eura za podršku njemačkoj kompaniji CureVac za ubrzavanje rada na vakcini protiv koronavirusa. Te se informacije pojavljuju dan nakon što su njemački vladini izvori rekli da je administracija Donalda Trumpa tražila način da se dobije pristup ovoj potencijalnoj cjepivi. Da li to znači da postoji samo jedna kompanija koja radi na rješenju koje je toliko važno za čovječanstvo? WHO (Svjetska zdravstvena organizacija) na svojim web stranicama objavljuje podatke o 13 takvih kompanija, a baza podataka Global Data ukazuje na 30 institucija koje rade na ovoj temi. Dakle, postoje li šanse za brzi lijek za naše probleme? Đavo je uvijek u detaljima.
Službeno, postoji samo jedna kompanija - američka Moderna - koja je prošla fazu kliničkog ispitivanja gdje se cjepivo testira na ljudima. Testovi se provode u Sjedinjenim Američkim Državama na Washingtonskom institutu za zdravstvena istraživanja u Seattlu. Ovakav brzi razvoj potencijalne vakcine bez presedana je i bio moguć jer su naučnici mogli iskoristiti iskustvo s koronavirusima koji su izazvali epidemiju SARS-a i MERS-a. Unatoč rekordnom radu, čak i ako se cjepivo pokaže sigurnim i efikasnim protiv virusa, neće biti na raspolaganju najmanje godinu dana.
Svi ostali igrači koji žele razviti vakcinu protiv coronavirusa trenutno su u najnaprednijoj pretkliničkoj fazi. Predklinička faza je istraživanje u laboratorijama i životinjama koje mogu dovesti samo do cijepljenja za oko godinu i pol dana. Teško je reći tko pobjeđuje u utrci za cjepivo, ali najveće šanse nisu startapovi, već velike farmaceutske kompanije.

Njemačka tvrtka CureVac surađuje s javnom institucijom sa sjedištem u Oslu, tzv Koalicija za pripravnost za epidemiju (CEPI). Rade na vakcini na bazi mRNA. Poput američke gigante Moderne mRNA, CureVac želi dokazati da će se mRNA cjepiva razviti i proizvesti brže od tradicionalnih cjepiva, te namjerava početkom ovog ljeta krenuti u klinička ispitivanja faze I.
Poput CureVac-a, njemačka kompanija BioNTech, koja razvija mRNA cjepiva protiv raka i gripe, predmet je potencijalnog partnerstva s farmaceutskim gigantom Pfizer-om radi razvoja cjepiva protiv virusa Covid19. Sanofi i Janssen surađuju s Američkim naprednim uredom za istraživanje i razvoj biomedicinske medicine (BARDA), a također su u pretkliničkoj fazi.
U toku su i mnogi manji projekti. U ponedjeljak je danskom javno-privatnom konzorcijumu dodijeljeno 7 milijuna eura subvencija u okviru programa Horizon2020: biotehnološke kompanije ExpreS2ion Biotechnologies i AdaptVac. Konzorcijum namerava da pokrene kliničko ispitivanje faze I / IIa za vakcinu u roku od 12 meseci.

Iako će najstarija cjepiva biti u pretkliničkoj fazi do ljeta, regulatorima će vjerojatno trebati jedna do dvije godine testiranja na ljudima kako bi osigurali da je cjepivo sigurno i efikasno. Nakon dobivanja odobrenja, kompanije mogu započeti proizvodnju i distribuciju cjepiva u komercijalnom obimu, što takođe traje dugo vremena. Ukratko, svijet vidi odobrenu vakcinu protiv Covid-19 tek oko sredine 2121. godine.
Međutim, ispostavilo se da vakcina nije jedini spas. Mnoge kompanije očekuju da će razviti nove antivirusne lijekove ili prilagoditi trenutne eksperimentalne lijekove za borbu protiv novog virusa. To je težak zadatak, jer se za razliku od bakterija virusi skrivaju u našim vlastitim ćelijama. To znači da lijekovi koji zaustavljaju virus češće utječu na naše stanice, što može izazvati nuspojave.
Pariska kompanija Iktos koja se bavi proizvodnjom lijekova umjetnom inteligencijom započela je suradnju s američkom hemijskom kompanijom SRI International. Cilj suradnje je razviti nove antivirusne lijekove za liječenje Covid19 i drugih vrsta virusa. Austrijska biotehnološka kompanija Apeiron započela je krajem februara pilot-kliničko ispitivanje lijeka kandidata protiv Covid-19. Proteinski lijek je već završio studije faze I i II u liječenju akutnih ozljeda pluća i očekuje se da djeluju oponašajući protein s kojim se koronavirus veže za vrijeme invazije na pluća. postoji i mnogo projekata usmjerenih na promjenu upotrebe odobrenih antivirusnih lijekova u liječenju Covid-19. To ima prednost što je sigurnost lijeka već poznata i može brže stići na tržište. Istraživači iz Göttingena i Berlina u Njemačkoj trenutno istražuju potencijal kamostat mezilata - lijeka koji je u Japanu odobren za liječenje pankreatitisa.

http: //www.e-manus.pl/

BioNTech, moderna, curevac, covid-19, coronavirus, vaccine:
20200320AD
BTM Innovations, public-private partnership, Apeiron, SRI International, Iktos, antiviral drugs, AdaptVac, ExpreS2ion Biotechnologies, pfizer, janssen, sanofi, 

On March 16, the European Commission announced that it offered EUR 80 million in support to the German company CureVac to accelerate work on the coronavirus vaccine. This information appears the day after German government sources said the Donald Trump administration was looking for a way to get access to this potential vaccine. Does this mean that there is only one company that is working on a solution that is so important for humanity? WHO (World Health Organization) publishes data on 13 such companies on its pages, and the Global Data database indicates 30 institutions working on the topic. So are there any chances for a quick remedy for our troubles? The devil is always in the details.
Officially, there is only one company - American Moderna - that has gone to the phase of clinical trials where the vaccine is being tested on humans. Tests are conducted in the United States at the Washington Institute of Health Research in Seattle. Such rapid development of a potential vaccine is unprecedented and was possible because scientists were able to use the experience of related coronaviruses that caused SARS and MERS epidemics. Despite record fast work, even if the vaccine proves safe and effective against the virus, it will not be available for at least a year.
All other players seeking to develop a coronavirus vaccine are currently at most pre-clinical stage. The preclinical stage is research in laboratories and animals that can only lead to vaccines in about a year and a half. It's hard to say who wins the race for the vaccine, but the biggest chances are not start-ups, but big drug companies.

The German company CureVac cooperates with a public institution based in Oslo, the so-called Coalition for Epidemic Preparedness (CEPI). They are working on an mRNA-based vaccine. Like the American giant Moderna mRNA, CureVac wants to prove that mRNA vaccines will be developed and manufactured faster than traditional vaccines and intends to move to Phase I clinical trials early this summer.
Like CureVac - the German company BioNTech, which develops mRNA vaccines for cancer and influenza - is the subject of a potential partnership with the pharmaceutical giant Pfizer to develop a vaccine for the Covid-19 virus. Sanofi and Janssen cooperate with the American Biomedical Advanced Office for Research and Development (BARDA) and are also at a preclinical stage.
Many smaller projects are also underway. On Monday, EUR 2.7 million in subsidies under Horizon 2020 was allocated to the Danish public-private consortium: biotechnology companies ExpreS2ion Biotechnologies and AdaptVac. The consortium intends to launch a phase I / IIa clinical trial for the vaccine within 12 months.

While the earliest vaccines may be in Phase I preclinical studies up to summer, regulatory authorities will probably require one to two years of human testing to ensure that the vaccine is safe and effective. After obtaining approval, companies can start producing and distributing the vaccine on a commercial scale, which also takes a long time. In summary, the world can see the approved Covid-19 vaccine only around mid-2021.
However, it turns out that the vaccine is not the only salvation. Many companies expect to develop new antiviral drugs or adapt current experimental drugs to fight the new virus. This is a difficult task, because unlike bacteria, viruses hide in our own cells. This means that medicines that stop viruses affect our cells more often, which can cause side effects.
The Paris company Iktos, dealing in the creation of drugs using artificial intelligence, has started cooperation with the American chemical company SRI International. The goal of the collaboration is to develop new antiviral drugs for the treatment of Covid-19 and other types of viruses. The Austrian biotechnology company Apeiron began a phase II pilot clinical trial of the candidate drug against Covid-19 at the end of February. The protein drug has already completed Phase I and II studies in the treatment of acute lung injury and is expected to act by mimicking the protein with which coronavirus binds during lung invasion. there are also many projects aimed at changing the use of approved antiviral drugs for the treatment of Covid-19. This has the advantage that the drug's safety is already known and can reach the market faster. Researchers at institutions in Göttingen and Berlin, Germany, are currently investigating the potential of kamostat mesylate - a drug approved in Japan for the treatment of pancreatitis.

http://www.e-manus.pl/